COPD - Association pulmonaire du Québec · COPD involves two respiratory problems, i.e. chronic...
-
Upload
phamkhuong -
Category
Documents
-
view
216 -
download
0
Transcript of COPD - Association pulmonaire du Québec · COPD involves two respiratory problems, i.e. chronic...
VENTOLIN® MDI
100 µgsalbutamol
VENTOLIN®
DISKUS®
200 µgsalbutamol
AIROMIR®
MDI
100 µgsalbutamol
Short-acting bronchodilators
ONBREZ®
BREEZHALER®
75 µgindacaterol maleate
SEREVENT® DISKUS®
50 µgsalmeterol xinafoate
OXEZE® TURBUHALER®
6 µg • 12 µgformoterol fumarate
Long-acting bronchodilators
SEEBRI® BREEZHALER®
50 μg glycopyrronium
SPIRIVA® RESPIMAT®
2,5 μg tiotropium bromide
INCRUSE® ELLIPTA®
62,5 μg umeclidinium
TUDORZA® GENUAIR®
400 μgaclidinium bromide
SPIRIVA®
HANDIHALER®
18 μgtiotropium bromide
Long-acting muscarinic antagonist
COMBIVENT®
RESPIMAT®
20/100 μgIpratropium bromide and salbutamol
Combination medication (short-acting muscarinic antagonist and short-acting bronchodilator)
ATROVENT ®
MDI
20 µgipratropium bromide
Short-acting muscarinic antagonist
COPD involves two respiratory problems, i.e. chronic bronchitis and emphysema. These two conditions cause a gradual obstruction of the respiratory tract. Afflicted individuals may suffer from either of the two illnesses or both at the same time.
Sufferers may exhibit one or several of the following symptoms:
•Shortness of breath•Chronic cough•Secretions (mucus)
Chronic bronchitis is characterized by permanent bronchial inflamma-tion and excessive production of mucus, which hampers the flow of air to the lungs.
Emphysema affects the alveoli of the lungs. It causes dilation of the alveoli and destruction of the alveolar walls. The air remains trapped in the damaged alveoli, thus making it difficult to breathe. Gaseous exchanges are also affected by the destruction of the alveolar tissue.
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
SIGNS AND SYMPTOMS
EMPHYSEMACHRONIC BRONCHITIS
INHALATION CHAMBER
Did you know that inhalers used without an inhalation chamber propel only 10% of the medication into the lungs and that almost 80% of the medication is simply deposited in the mouth? All inhalers should be used with an inhalation chamber. As a result, you will:•Optimize the administration of the drug (better deposition, better synchronization and simpler technique);•Reduce the side effects of certain drugs.
Selected list of controllers
BRICANYL®
TURBUHALER®
0.5 mgterbutaline sulfate
Normal airway Normal airway
Inflammation
Mucus
Damaged alveoli
Chronic bronchitis Emphysème
FLOVENT® MDI
50 µg • 125 µg 250 µgfluticasone propionate
PULMICORT® TURBUHALER®
100 µg • 200 µg 400 µgbudesonide
Inhaled corticosteroids
FLOVENT® DISKUS®
50 µg • 100 µg 250 µg • 500 µgfluticasone propionate
BREO® ELLIPTA®
100/25 µgfluticasone furoate and vilanterol
ADVAIR®
MDI
125/25 µg 250/25 µgfluticasone propionate and salmeterol
SYMBICORT®
TURBUHALER®
100/6 µg • 200/6 µgbudesonide and formoterol fumarate
Combination medications (inhaled corticosteroids and long-acting bronchodilators)
ADVAIR® DISKUS®
100/50 µg • 250/50 µg 500/50 µgfluticasone propionate and salmeterol
ANORO®
ELLIPTA®
62.5/25 µgumeclidinium and vilanterol
ULTIBRO® BREEZHALER®
50/110 µgglycopyrronium and indacaterol maleate
DUAKLIR® GENUAIR®
400/12 μgaclidinium bromide and formoterol fumarate
INSPIOLTO® RESPIMAT®
2,5/2,5 μgtiotropium bromide and olodaterol hydrochloride
Combination medications (Long-acting muscarinic antagonist and long-acting bronchodilators)
•Increasingly frequent respiratory infections and slower recovery•Fatigue•Reduced ability to pursue everyday activities
COPDMEDICATIONS CHART
Selected list of relievers
Head office : 6070 Sherbrooke Street East, office 104Montreal (Quebec) H1N 1C1www.pq.lung.ca